Unlocking the Secrets of P63-Associated Disorders: How New Research Offers Hope for Skin Health

The p63 protein, a member of the p53 family, is crucial for maintaining skin health. It functions within the stratified epithelia, particularly the epidermis, where it regulates gene expression. A key role of p63 is to support mechanical resistance in the skin. It achieves this by positively regulating epidermal genes involved in cell-matrix adhesion and cell-cell adhesion. Adequate p63 function is essential, and its deficiency can lead to severe defects in stratified epithelia and related structures, thereby affecting overall health. This is crucial for processes like wound healing and the integrity of the skin barrier.

EEC syndrome is characterized by central reduction defects in the hands and feet, along with cleft lip and/or palate. This condition often arises from mutations in the DNA-binding domain of the p63 gene, which disrupts p63's ability to bind. In contrast, AEC syndrome presents with severe skin symptoms, including congenital erythroderma, skin fragility, atrophy, palmo-plantar hyperkeratosis, and extensive, long-lasting erosive lesions. While EEC primarily affects limb development and facial features, AEC predominantly impacts skin integrity and barrier function. Both are linked to p63 mutations, but the specific mutations and resulting clinical presentations differ significantly. For instance, in the AEC syndrome, the mutation L514F in the p63 gene can lead to skin erosions, while EEC frequently involves mutations that disrupt p63's DNA-binding capabilities.

The L514F mutation in p63, found in AEC patients, disrupts the normal function of p63, leading to various skin problems. This mutation results in skin atrophy and delayed wound healing due to a reduced number of epidermal stem cells. This reduction is caused by compromised fibroblast growth factor receptor signaling and downregulation of Fgfr2 and Fgfr3, which are p63 target genes. Additionally, desmosomes, essential cell junctions for mechanical resistance, are weakened, leading to reduced cell adhesion. The skin erosions, a hallmark of AEC syndrome, are also caused by reduced mechanical strength, acantholysis, and cytolysis of the basal layer, further highlighting the critical role of p63 in maintaining skin structure and integrity.

TSLP, an IL-7-like cytokine, plays a critical role in the inflammatory and autoimmune responses seen in AEC mice. Skin erosions trigger local and systemic inflammatory responses that depend on TSLP. TSLP is produced by keratinocytes in response to epidermal barrier failure. In AEC mice, TSLP circulates in the blood, causing the expansion of pre-B cells and leading to an autoimmune B-cell proliferative disorder. When TSLP is ablated in the epidermis of AEC mice, the skin and systemic inflammation is reduced. The B-cell differentiation is also rescued and mortality is reduced. This indicates that TSLP is a key driver of the inflammatory and autoimmune aspects of AEC syndrome.

Understanding p63-associated disorders provides several avenues for potential breakthroughs in treating conditions like AEC syndrome. Research into the genetic mechanisms, such as the impact of the L514F mutation, reveals the specific pathways disrupted, like fibroblast growth factor receptor signaling and desmosome function. By identifying these mechanisms, researchers can explore targeted therapies. For example, understanding the role of TSLP in inflammation opens the door for treatments that inhibit TSLP or its downstream effects. Furthermore, the development of novel conditional mouse models allows for studying treatments' effects on specific issues, like skin erosions, without the confounding issues of the cleft palate. The identification of p63 target genes provides opportunities for gene therapies or small-molecule drugs that can restore the normal function of these genes. Therefore, a deeper understanding of the disorder can offer targeted treatments.